- Home
- AVY vs UTHR Comparison
AVY vs UTHR Comparison
Compare AVY & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVY
- UTHR
- Stock Information
- Founded
- AVY 1935
- UTHR 1996
- Country
- AVY United States
- UTHR United States
- Employees
- AVY N/A
- UTHR N/A
- Industry
- AVY Containers/Packaging
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- AVY Consumer Discretionary
- UTHR Health Care
- Exchange
- AVY Nasdaq
- UTHR Nasdaq
- Market Cap
- AVY 16.8B
- UTHR 16.2B
- IPO Year
- AVY N/A
- UTHR 1999
- Fundamental
- Price
- AVY $188.15
- UTHR $359.23
- Analyst Decision
- AVY Buy
- UTHR Buy
- Analyst Count
- AVY 12
- UTHR 14
- Target Price
- AVY $242.72
- UTHR $370.86
- AVG Volume (30 Days)
- AVY 597.8K
- UTHR 313.6K
- Earning Date
- AVY 01-29-2025
- UTHR 02-19-2025
- Dividend Yield
- AVY 1.87%
- UTHR N/A
- EPS Growth
- AVY 40.44
- UTHR 25.10
- EPS
- AVY 8.33
- UTHR 22.72
- Revenue
- AVY $8,680,500,000.00
- UTHR $2,756,200,000.00
- Revenue This Year
- AVY $5.94
- UTHR $26.32
- Revenue Next Year
- AVY $4.86
- UTHR $10.37
- P/E Ratio
- AVY $22.58
- UTHR $15.82
- Revenue Growth
- AVY 4.84
- UTHR 25.04
- 52 Week Low
- AVY $185.73
- UTHR $208.62
- 52 Week High
- AVY $233.48
- UTHR $417.82
- Technical
- Relative Strength Index (RSI)
- AVY 28.06
- UTHR 43.90
- Support Level
- AVY $185.73
- UTHR $358.82
- Resistance Level
- AVY $193.39
- UTHR $383.00
- Average True Range (ATR)
- AVY 3.60
- UTHR 9.97
- MACD
- AVY -1.41
- UTHR -0.80
- Stochastic Oscillator
- AVY 11.68
- UTHR 29.51
About AVY Avery Dennison Corporation
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification, or RFID, inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
About UTHR United Therapeutics Corporation
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.